Role of siRNA in breast cancer

1. Role of siRNA in Breast Cancer

2. Introduction
2
 Gene silencing by RNAi was first observed by Craig Mello in C. elegans
 Small interfering RNAs (siRNAs) are non-coding RNAs (20-25 nucleotides)
 siRNA is a posttranscriptional mode of gene regulation
 Breast cancer is the most commonly diagnosed form of cancer
 Small interfering RNA (siRNA) is a promising tool in breast cancer therapy

3. Mechanism
3
Adapted from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845562/

4. Potential Targets
4
HER2 expression
 Estrogen receptor applied in therapeutic target
 Cofactor protein and NFAT3
 Regulate the ER gene transcriptional activity
 Silencing NFAT3 using siRNA
 Reduces ER positive breast cancer cell growth
 NFAT3 potential siRNA therapeutic targets
Adapted from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845562/

5. Mode of Delivery
5

6. Conclusion
6
 siRNA thus holds incredibly promising potential as a form of gene therapy for
not only breast cancer but possibly other cancers and diseases as well
 Challenge posed by siRNA is the safe and efficient delivery of siRNA to the
desired organ and subsequently into target cells
 It is postulated that RNAi-based therapy will be used as a new method of
cancer therapy in the near future

7. References
7
 https://pdfs.semanticscholar.org/d098/c1040784a0af7600a3a09c2d74b0a4515315.pdf
 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845562
 https://link.springer.com/chapter/10.1007/978-1-59745-222-9_11
 http://www.oncm.org/v03p0074.htm
 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958528
 https://erc.bioscientifica.com/view/journals/erc/24/4/R81.xml
 https://www.sciencedirect.com/science/article/pii/S1818087618306330